Karolinska Development's Modus Therapeutics Gets Approval For 2nd Part Of Phase 2 Study
Refinitiv1分未満で読めます
Karolinska Development AB KDEV:
REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY MODUS THERAPEUTICS RECEIVES APPROVAL FOR SECOND PART OF PHASE 2 STUDY IN CHRONIC KIDNEY DISEASE WITH ANEMIA
ログイン、もしくは永年無料のアカウントを作成して、このニュースを読みましょう